Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Dermira (NASDAQ: DERM) today and set a price target of $20. The company’s shares closed yesterday at $8.78, close to its 52-week low of $6.98.
Chen wrote:
“DERM is a leading dermatology company with pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12- month price target of $20. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $20.”
According to TipRanks.com, Chen has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.6% and a 38.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.
Dermira has an analyst consensus of Moderate Buy, with a price target consensus of $18.
See today’s analyst top recommended stocks >>
Based on Dermira’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $59.25 million. In comparison, last year the company had a GAAP net loss of $38.57 million.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DERM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne.
